NCT05738083 Multi-Center Registry Cohort Study on Prognostic Factors and Prediction Model Construction in Aneurysmal SAH
| NCT ID | NCT05738083 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital of Nanchang University |
| Condition | Aneurysmal Subarachnoid Hemorrhage |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2018-10-01 |
| Primary Completion | 2028-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2018-10-01 with a primary completion date of 2028-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PROSAH-MPC, a collaborative research project among neurosurgical centers in China, focuses on aneurysmal subarachnoid hemorrhage (aSAH). Its aim is to identify prognostic factors and develop robust prediction models for complications, disability, and mortality in aSAH patients. By leveraging a large, multi-center, prospective cohort design, PROSAH-MPC aims to overcome limitations of past studies and provide a more comprehensive understanding of the disease.
Eligibility Criteria
Inclusion Criteria: * Subarachnoid hemorrhage confirmed by computed tomography (CT); * Cerebral angiography (CTA) and digital subtraction angiography (DSA) examination confirming intracranial aneurysm rupture as the cause of the subarachnoid hemorrhage; * Blood routine, biochemical function, blood coagulation function, and craniocerebral CT performed within 24 hours of symptom onset; * Underwent aneurysm clipping by surgery or endovascular embolization within 72 hours after-onset. Exclusion Criteria: * Aneurysm rupture bleeding time exceeding 24 hours before hospital admission; * Incomplete image data or blood test information; * Long-term use of anticoagulant medications such as aspirin or warfarin; * Admitted to hospital with active infectious diseases; * long-term anticoagulant drugs such as aspirin, wave dimensions; * Presence of other intracranial vascular malformations.
Contact & Investigator
Xingen Zhu, Prof
STUDY CHAIR
Second Affiliated Hospital of Nanchang University
Frequently Asked Questions
Who can join the NCT05738083 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Aneurysmal Subarachnoid Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05738083 currently recruiting?
Yes, NCT05738083 is actively recruiting participants. Contact the research team at zxg2008vip@163.com for enrollment information.
Where is the NCT05738083 trial being conducted?
This trial is being conducted at Nanchang, China.
Who is sponsoring the NCT05738083 clinical trial?
NCT05738083 is sponsored by Second Affiliated Hospital of Nanchang University. The principal investigator is Xingen Zhu, Prof at Second Affiliated Hospital of Nanchang University. The trial plans to enroll 5,000 participants.